MICOT PHARMA-B (02335) has announced the completion of a Phase II clinical trial for its self-developed candidate drug MT200605, designed to treat acute ischemic stroke (AIS).
The trial demonstrated notable and consistent efficacy advantages alongside a favorable safety profile, according to the company's official statement.
This milestone marks a significant step forward in the group's pipeline, with the candidate showing robust therapeutic potential in addressing a critical medical need.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.